On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases, announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10 billion, or approximately $8.8 billion net of estimated cash acquired. Wilson Sonsini Goodrich & Rosati is patent counsel to Crinetics and advised the company on patent matters related to the transaction.

The transaction was unanimously approved by the Vertex’s and Crinetics’ boards of directors and is expected to close in the third quarter of 2026, subject to customary closing conditions.

The Wilson Sonsini team that has advised Crinetics on patent matters includes Mike Hostetler, Uale Taotafa, Val Zunic, Tyler Baguley, and Michael Wormald.

For more information, please see Vertex's and Crinetics' joint news release. Additional coverage can be found on Reuters and Fierce Pharma.